Eyenovia Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
64
- Stock Symbol
-
EYEN
- Share Price
-
$0.54
- (As of Friday Closing)
Eyenovia General Information
Description
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Contact Information
Website
www.eyenoviabio.comCorporate Office
- 295 Madison Avenue
- Suite 2400
- New York, NY 10017
- United States
Corporate Office
- 295 Madison Avenue
- Suite 2400
- New York, NY 10017
- United States
Eyenovia Timeline
Eyenovia Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.54 | $0.54 | $0.37 - $2.57 | $41.3M | 76.9M | 1.74M | -$0.78 |
Eyenovia Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 40,663 | 87,060 | 48,708 | 107,410 |
| Revenue | 31 | 4 | 0 | 14,000 |
| EBITDA | (34,023) | (24,800) | (26,407) | (12,172) |
| Net Income | (37,282) | (27,261) | (28,011) | (12,778) |
| Total Assets | 18,995 | 28,779 | 31,036 | 31,659 |
| Total Debt | 15,662 | 16,081 | 10,123 | 7,150 |
Eyenovia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eyenovia Comparisons
Industry
Financing
Details
000000
000000
Eyenovia Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals | Corporation | Watertown, MA | 000 | 00000 | 00000000 | 00000 |
| Ocular Therapeutix | Formerly VC-backed | Bedford, MA | 000 | 00000 | 00000000 | 00000 |
| Medical Information Technology | Formerly PE-Backed | Canton, MA | 0000 | 00000000 | ||
| Clearside Biomedical | Formerly VC-backed | Alpharetta, GA | 00 | 00000 | 00000000 | 00000 |
| Novaliq | Venture Capital-Backed | Heidelberg, Germany | 00 | 00000 | 0000000000 0 | 00000 |
Eyenovia Patents
Eyenovia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230173118-A1 | Pulsed ultraviolet in-line sterilization system for primary drug containers | Pending | 03-Dec-2021 | 00000000 | |
| AU-2020399803-A1 | Systems and devices for delivering fluids to the eye and methods of use | Pending | 11-Dec-2019 | 0000000000 | |
| US-20210177650-A1 | Systems and devices for delivering fluids to the eye and methods of use | Pending | 11-Dec-2019 | 0000000000 | |
| CA-3164288-A1 | Systems and devices for delivering fluids to the eye and methods of use | Pending | 11-Dec-2019 | 0000000000 | |
| JP-2023506781-A | Systems and devices for delivering fluids to the eye and methods of use | Pending | 11-Dec-2019 | A61F9/0008 |
Eyenovia Executive Team (8)
| Name | Title | Board Seat |
|---|---|---|
| Michael Rowe | Chief Executive Officer & Board Member | |
| John Gandolfo | Chief Financial Officer, Finance & Chief Accounting Officer, Accounting | |
| Bren Kern | Chief Operating Officer, Operations | |
| Tsontcho Lanchulev | Founder & Chairman |
Eyenovia Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Charles Mather | Self | Board Member | 000 0000 |
| Ellen Strahlman | Self | Board Member | 000 0000 |
| Ernest Mario Ph.D | Self | Board Member | 000 0000 |
| Kenneth Lee Jr. | Self | Lead Director | 000 0000 |
| Michael Rowe | Eyenovia | Chief Executive Officer & Board Member | 000 0000 |
Eyenovia Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Eyenovia ESG
Risk Overview
Risk Rating
Updated February, 14, 2024
33.42 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
Eyenovia FAQs
-
When was Eyenovia founded?
Eyenovia was founded in 2014.
-
Who is the founder of Eyenovia?
Tsontcho Lanchulev is the founder of Eyenovia.
-
Who is the CEO of Eyenovia?
Michael Rowe is the CEO of Eyenovia.
-
Where is Eyenovia headquartered?
Eyenovia is headquartered in New York, NY.
-
What is the size of Eyenovia?
Eyenovia has 64 total employees.
-
What industry is Eyenovia in?
Eyenovia’s primary industry is Other Healthcare Technology Systems.
-
Is Eyenovia a private or public company?
Eyenovia is a Public company.
-
What is Eyenovia’s stock symbol?
The ticker symbol for Eyenovia is EYEN.
-
What is the current stock price of Eyenovia?
As of 13-Sep-2024 the stock price of Eyenovia is $0.54.
-
What is the current market cap of Eyenovia?
The current market capitalization of Eyenovia is $41.3M.
-
What is Eyenovia’s current revenue?
The trailing twelve month revenue for Eyenovia is $31.4K.
-
Who are Eyenovia’s competitors?
EyePoint Pharmaceuticals, Ocular Therapeutix, Medical Information Technology, Clearside Biomedical, and Novaliq are some of the 19 competitors of Eyenovia.
-
What is Eyenovia’s annual earnings per share (EPS)?
Eyenovia’s EPS for 12 months was -$0.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
